Suramin in Treating Patients With Recurrent Primary Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002639|
Recruitment Status : Completed
First Posted : May 26, 2004
Last Update Posted : June 21, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary brain tumors following radiation therapy.
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors||Drug: chemotherapy Drug: suramin||Phase 2|
OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain tumors as measured by radiographic response, time to progression, and survival. II. Assess the toxic effects of suramin in this patient population.
OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936.
PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial response, a total of 25 patients will be entered over approximately 30 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS|
|Study Start Date :||July 1995|
|Study Completion Date :||May 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002639
|United States, Georgia|
|Department of Neurosurgery - Emory|
|Atlanta, Georgia, United States, 30322|
|Study Chair:||Jeffrey J. Olson, MD||Emory University|